Теоретичні та прикладні
питання економіки. Збірник наукових праць. Випуск 1/2 (40/41)
ORCID ID 0000-0002-2157-1422
0000-0002-8657-7278
0000-0002-6538-1241
DOI https://doi.org/10.17721/tppe.2020.41.4
Dvulit Z., Doctor of Economics, Professor
Lviv Polytechnic
National University
Mykytiuk O., PhD in Economics , Docent
Taras Shevchenko National University of
Kyiv
Onysenko T., PhD in Economics
Taras Shevchenko National University of
Kyiv
FEATURES OF MERGERS AND ACQUISITIONS IN
THE PHARMACEUTICAL INDUSTRY
Increasing mergers and
acquisitions in the pharmaceutical industry have raised fears that
unprecedented market concentration will weaken competition. Two of the most
important concerns for the pharmaceutical industry are concerns that these
mergers will reduce the market for new developments, and concerns that the
combination of large marketing efforts and sales will increase the influence of
individual pharmaceutical manufacturers and weaken competition in the industry.
This article argues
that none of the above dangers are systematically justified. However, there is
a potential risk of market concentration at the stage of regulatory approval of
mergers and acquisitions.
The rapid development
of the pharmaceutical industry in a pandemic leads to the need to combine
interests. That is why the consideration of the topic of mergers and
acquisitions on the example of the pharmaceutical industry is very relevant.
The article identifies
how these structural changes contribute to the current wave of mergers among
active pharmaceutical market participants and how the potential harm of
competition can be reduced.
Keywords: merger, acquisition,
merger agreements, pharmaceuticals, combination of interests, enterprise.
Full Text: PDF